The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC).
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Kristian Stensland
No Relationships to Disclose
 
John Sfakianos
No Relationships to Disclose
 
Russell Bailey McBride
No Relationships to Disclose
 
Reza Mehrazin
No Relationships to Disclose
 
Che-Kai Tsao
No Relationships to Disclose
 
Paolo Boffetta
No Relationships to Disclose
 
William K. Oh
Honoraria - Amgen; Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Dendreon; Janssen Biotech; Pfizer; Sanofi